Thurston Springer Miller Herd & Titak Inc. Has $59,000 Position in Solventum Co. (NYSE:SOLV)

Thurston Springer Miller Herd & Titak Inc. grew its position in Solventum Co. (NYSE:SOLV) by 69.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 891 shares of the company’s stock after purchasing an additional 366 shares during the period. Thurston Springer Miller Herd & Titak Inc.’s holdings in Solventum were worth $59,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SOLV. Oak Thistle LLC acquired a new stake in shares of Solventum during the fourth quarter worth about $512,000. Czech National Bank increased its stake in Solventum by 6.5% during the 4th quarter. Czech National Bank now owns 29,966 shares of the company’s stock worth $1,980,000 after purchasing an additional 1,820 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in Solventum by 24.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock worth $3,103,000 after buying an additional 9,333 shares during the period. Nordea Investment Management AB lifted its stake in Solventum by 189.5% in the fourth quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock valued at $43,902,000 after buying an additional 431,986 shares in the last quarter. Finally, Everence Capital Management Inc. acquired a new position in shares of Solventum in the fourth quarter valued at approximately $305,000.

Analyst Ratings Changes

A number of equities research analysts recently commented on SOLV shares. Piper Sandler raised their price objective on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Wolfe Research assumed coverage on Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating on the stock. Mizuho assumed coverage on Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective for the company. Stifel Nicolaus started coverage on Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price on the stock. Finally, Morgan Stanley upped their price target on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $68.29.

Solventum Price Performance

NYSE:SOLV opened at $73.60 on Friday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The firm has a fifty day simple moving average of $69.09 and a 200 day simple moving average of $65.34. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.